Status:
WITHDRAWN
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)
Lead Sponsor:
Cerecin
Conditions:
Alzheimer's Disease
Eligibility:
All Genders
55-85 years
Phase:
PHASE2
PHASE3
Brief Summary
The study will evaluate the safety \& efficacy of AC-1204, a ketogenic compound, administered orally on a daily basis for 6 months. Following the 6 month double-blind phase of the study, subjects may ...
Detailed Description
Two primary outcome measures will be assessed in APOE4(-) patients: 1. differences from baseline between AC-1204 and placebo groups' ADAS-cog scores at 6 months 2. differences from baseline between A...
Eligibility Criteria
Inclusion
- Males/females between age of 55 -85 years
- MMSE scores between 16-26
- Probable mild to moderate AD
Exclusion
- Presence of other CNS disorders as alternative causes of dementia
- Type 1 or Type 2 diabetes
- Significant renal/hepatic disease
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01211782
Last Update
December 4 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meridien Research
St. Petersburg, Florida, United States, 33709